Zika virus disease
27 March 2017 -- WHO launches the first podcast episode in a series of 5, called Evidence in action, that focus on Zika virus infection. WHO's experience over 2016 has shown that Zika virus and the associated neurological complications represent a long-term public health challenge. These episodes range from tracing the disease to the long-term management of Zika virus syndrome.
2 February 2017 - "We are now in the long haul and we are all in this together," said Dr Margaret Chan, Director-General of WHO. "WHO's strategic planning and commitment to work with partners for sustained interventions and research should go a long way towards bracing the world for this challenging – and still heart-breaking – effort."
Social science research is an essential part of effective risk communication and community engagement for responding effectively to the ongoing Zika outbreak, as it is the case for any epidemic or pandemic. This interactive map allows you to gain an overview of such research to input into the response.
Knowledge Attitudes and Practice (KAP) surveys and other social science research allows responders to rapidly obtain valuable and insightful information in order to tailor interventions to better address people's needs at community level, thereby contributing to the overall public health response to Zika virus and its potential complications.
Science in action – interviews with Zika experts
Zika virus poses many questions and concerns for humanity. Scientists and experts are racing to understand the relationship between Zika virus infection and associated neurological complications. The Institut Pasteur, WHO and other partners convened researchers and public health experts working on this ongoing public health emergency to share preliminary results and discuss next steps.
These series of videos cover exclusive interviews with experts who work in a diversity of scientific domains: vector control, diagnostics, Zika and its neurological complications such as Guillain-Barré syndrome and microcephaly, as well as vaccine development for Zika.
Zika is a virus spread to humans by Aedes mosquitoes - the same mosquitoes that spread dengue, chikungunya and yellow fever. It usually causes mild illness, with most people sick with the virus getting a slight fever and skin rash. Others may also get conjunctivitis, muscle and joint pain, and feel tired. The symptoms usually finish in 2 to 7 days. The best protection from Zika virus is preventing mosquito bites.
- Zika virus disease is caused by a virus transmitted by Aedes mosquitoes.
- The virus is known to circulate in Africa, the Americas, Asia and the Pacific.
- People with Zika virus disease usually have a mild fever, skin rash (exanthema) and conjunctivitis. These symptoms normally last for 2-7 days.
- There is no specific treatment or vaccine currently available.
- The best form of prevention is protection against mosquito bites.
Weekly Epidemiological Record (WER)
Zika virus research agenda
Prevention of sexual transmission of Zika virus
Screening, assessment and management of neonates and infants with complications associated with Zika virus exposure in utero
Identification and management of Guillain-Barré syndrome
Pregnancy management in the context of Zika virus infection
Surveillance for Zika virus infection, microcephaly and Guillain-Barré syndrome
Knowledge, Attitudes and Practice surveys Zika virus disease and potential complications
Laboratory testing for Zika virus infection
Risk communication and community engagement for Zika virus prevention and control
- All publications and resources